Profile data is unavailable for this security.
About the company
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.
- Revenue in AUD (TTM)697.94k
- Net income in AUD-7.74m
- Incorporated1986
- Employees3.00
- LocationPrescient Therapeutics LtdL 4 100 Albert RdSOUTH MELBOURNE 3205AustraliaAUS
- Phone+61 39692-7222
- Fax+61 39077-9233
- Websitehttps://ptxtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cann Group Ltd | 16.45m | -29.28m | 18.71m | 40.00 | -- | 0.3617 | -- | 1.14 | -0.0724 | -0.0724 | 0.0406 | 0.1161 | 0.1237 | 0.3952 | 7.37 | -- | -22.03 | -22.28 | -34.23 | -24.43 | 21.11 | -- | -178.07 | -407.57 | 0.0861 | -5.88 | 0.5646 | -- | 114.90 | 89.76 | -27.66 | -- | -11.16 | -- |
| Noxopharm Ltd | 3.90m | -12.13m | 19.58m | 1.00k | -- | 2.98 | -- | 5.02 | -0.0415 | -0.0415 | 0.0134 | 0.0225 | 0.2684 | -- | 1.64 | 3,901.84 | -83.43 | -50.96 | -94.78 | -62.98 | -- | -- | -310.82 | -191.70 | -- | -1.47 | 0.00 | -- | 11.32 | 44.02 | 19.34 | -- | -- | -- |
| Immuron Ltd | 3.58m | -3.88m | 20.29m | 6.00 | -- | 1.16 | -- | 5.67 | -0.017 | -0.017 | 0.0157 | 0.0769 | 0.1664 | 0.6468 | 7.92 | 596,106.70 | -18.06 | -27.48 | -19.86 | -29.58 | 80.87 | 77.52 | -108.52 | -296.64 | 7.79 | -2.85 | 0.0023 | -- | 135.85 | -13.34 | -32.66 | -- | 3.27 | -- |
| Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 21.78m | -- | -- | 3.24 | -- | 18.04 | -0.0162 | -0.0162 | 0.0039 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -- | -120.26 | -- | -- | -- | -357.70 | -- | -- | -21.62 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Acrux Ltd | 14.46m | -709.00k | 22.39m | 43.00 | -- | 3.96 | -- | 1.55 | -0.0024 | -0.0024 | 0.0502 | 0.0195 | 1.29 | -- | 4.86 | -- | -6.34 | -39.91 | -9.21 | -46.00 | 72.38 | -- | -4.90 | -132.53 | -- | -- | 0.2861 | -- | 133.74 | 28.29 | 92.23 | -- | -16.66 | -- |
| BPH Energy Ltd | 345.67k | 894.65k | 22.95m | 2.00k | 20.41 | 0.9868 | -- | 66.40 | 0.001 | 0.001 | 0.0004 | 0.0203 | 0.0177 | -- | 5.97 | -- | 4.58 | -6.89 | 4.78 | -7.72 | 56.39 | -- | 258.50 | -357.76 | -- | -- | 0.0043 | -- | 96.54 | 5.21 | 179.13 | -- | -- | -- |
| LBT Innovations Limited | 2.00m | -21.38m | 24.14m | 17.00 | -- | 8.88 | -- | 12.04 | -0.0428 | -0.0428 | 0.0038 | 0.002 | 0.1087 | 0.0819 | 2.25 | 117,882.40 | -115.89 | -28.85 | -131.86 | -30.99 | 94.76 | -- | -1,066.62 | -441.76 | 3.30 | -6.85 | 0.5633 | -- | -5.29 | -18.45 | -239.17 | -- | -34.63 | -- |
| Alterity Therapeutics Ltd | 123.46k | -12.28m | 26.23m | 11.00 | -- | 0.7951 | -- | 212.42 | -0.005 | -0.005 | 0.00005 | 0.0063 | 0.0044 | -- | 1.52 | 11,223.64 | -44.20 | -53.02 | -53.57 | -61.96 | -- | -- | -9,947.97 | -40,995.62 | -- | -- | 0.0143 | -- | 557.60 | -39.40 | -7.47 | -- | -34.88 | -- |
| Invion Ltd | 4.46m | -1.50m | 32.12m | 8.00 | -- | 1.80 | -- | 7.20 | -0.0002 | -0.0002 | 0.0007 | 0.0028 | 0.2345 | -- | 3.20 | -- | -7.88 | -16.93 | -8.12 | -18.13 | -- | -- | -33.60 | -51.63 | -- | -- | 0.00 | -- | 25.72 | 41.18 | 27.95 | -- | -- | -- |
| BCAL Diagnostics Ltd | 3.67m | -5.00m | 33.00m | -- | -- | 4.35 | -- | 8.98 | -0.0227 | -0.0227 | 0.0166 | 0.0241 | 0.4493 | -- | 3.21 | -- | -61.10 | -54.01 | -67.83 | -62.57 | -- | -- | -136.00 | -248.64 | -- | -131.83 | 0.1985 | -- | 298.63 | 63.18 | -49.51 | -- | 91.62 | -- |
| Syntara Ltd | 9.83m | -14.26m | 34.63m | 107.00 | -- | 3.84 | -- | 3.52 | -0.0197 | -0.0172 | 0.0136 | 0.0075 | 0.442 | 1.58 | 2.22 | -- | -64.13 | -27.33 | -97.76 | -34.23 | 81.69 | 88.37 | -145.11 | -61.99 | 1.75 | -262.59 | 0.0674 | -- | 23.60 | -18.30 | -486.78 | -- | -31.06 | -- |
| Prescient Therapeutics Ltd | 697.94k | -7.74m | 34.63m | 3.00 | -- | 1.53 | -- | 49.62 | -0.0098 | -0.0098 | 0.0009 | 0.0281 | 0.0276 | -- | 2.32 | -- | -30.58 | -27.61 | -32.59 | -29.03 | -- | -- | -1,109.58 | -3,284.78 | -- | -412.91 | 0.00 | -- | 939.16 | 29.68 | -36.88 | -- | -- | -- |
| Little Green Pharma Ltd | 25.63m | -8.15m | 34.70m | -- | -- | 0.4467 | -- | 1.35 | -0.0272 | -0.0272 | 0.0856 | 0.2574 | 0.2772 | 1.05 | 12.29 | -- | -8.82 | -- | -9.74 | -- | 53.18 | -- | -31.81 | -- | 1.39 | -18.90 | 0.0624 | -- | 29.07 | -- | 4.72 | -- | -- | -- |
| Starpharma Holdings Ltd | 10.63m | -8.40m | 39.97m | 50.00 | -- | 1.16 | -- | 3.76 | -0.0205 | -0.0205 | 0.0259 | 0.0837 | 0.2092 | 0.282 | 2.10 | -- | -16.53 | -28.47 | -20.70 | -33.66 | 92.67 | 71.62 | -79.00 | -391.82 | 5.22 | -- | 0.0833 | -- | -14.10 | -3.22 | 3.19 | -- | 11.58 | -- |
| Biotron Ltd | 1.65m | -4.02m | 45.11m | 4.00 | -- | 24.13 | -- | 27.42 | -0.0045 | -0.0045 | 0.0018 | 0.0021 | 0.3587 | -- | -- | -- | -87.73 | -64.30 | -103.46 | -74.43 | -156.30 | -108.03 | -244.54 | -231.62 | -- | -- | 0.0148 | -- | -8.16 | -2.48 | -25.59 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Prescient Therapeutics Ltd's reporting currency: Australian Dollar AUD
0.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 406.50k | 0.05% |
| DFA Australia Ltd.as of 31 May 2023 | 57.23k | 0.01% |
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
